Sugi Predict

Sugi Predict / Compounds / SCHEMBL2566030

SCHEMBL2566030

SCHEMBL2566030

CCOC(=O)C(C#N)C(C)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ MMP8 P22894 1/20 0.48
▸ GAA P10253 3/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ MAPK1 P28482 1/20 0.46
▸ PIN1 Q13526 1/20 0.44
▸ NPC1 O15118 1/20 0.43
▸ MAPT P10636 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ LMNA P02545 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ GABRA1 P14867 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ GABRB2 P47870 1/20 0.40
▸ SLC6A2 P23975 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL490341 0.86 SMN1; SMN2 (0.53) SMN1; SMN2L3MBTL1MMP8GAAMEN1
SCHEMBL27744339 0.84 SMN1; SMN2 (0.52) SMN1; SMN2L3MBTL1MMP8GAAMEN1
SCHEMBL22262872 0.84 SMN1; SMN2 (0.52) SMN1; SMN2L3MBTL1MMP8GAAMEN1
SCHEMBL10982403 0.84 KMT2A (0.53) SMN1; SMN2GAAMEN1KMT2ATSHR
SCHEMBL28676130 0.84 ALOX15 (0.43) SMN1; SMN2L3MBTL1GAAMEN1KMT2A
SCHEMBL19388060 0.83 SMN1; SMN2 (0.51) SMN1; SMN2L3MBTL1MMP8GAAMEN1
SCHEMBL11042097 0.82 CYP3A4 (0.43) SMN1; SMN2L3MBTL1GAAMEN1KMT2A
SCHEMBL12506132 0.82 SMN1; SMN2 (0.50) SMN1; SMN2L3MBTL1MMP8GAAMEN1
SCHEMBL27590151 0.80 TSHR (0.45) SMN1; SMN2MAPK1TSHRLMNA
SCHEMBL7247968 0.80 SMN1; SMN2 (0.54) SMN1; SMN2L3MBTL1MMP8GAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260043010-A1 ENONE REDUCTASES CODEXIS, INC. (US) 2026-02-12 — — US disclosed
US-12371674-B2 Enone reductases CODEXIS, INC. (US) 2025-07-29 — — US disclosed
US-20210324344-A1 ENONE REDUCTASES INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2021-10-21 — — US disclosed
US-20210324344-A1 ENONE REDUCTASES INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2021-10-21 — — US disclosed
US-10995321-B2 Enone reductases CODEXIS, INC. (US) 2021-05-04 — — US disclosed
US-10995321-B2 Enone reductases CODEXIS, INC. (US) 2021-05-04 — — US disclosed
US-20200040311-A1 ENONE REDUCTASES INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2020-02-06 — — US disclosed
US-20200040311-A1 ENONE REDUCTASES INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2020-02-06 — — US disclosed
US-20180312815-A1 ENONE REDUCTASES INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2018-11-01 — — US disclosed
US-10035988-B2 Enone reductases CODEXIS, INC. (US) 2018-07-31 — — US disclosed
EP-2382308-A2 ENONE REDUCTASES Codexis, Inc. (US) 2011-11-02 — — EP disclosed
US-20100292292-A1 Treatment of Neurodegenerative Diseases Using Indatraline Analogs LINK MEDICINE CORPORATION (US) 2010-11-18 — — US disclosed
US-20100190218-A1 ENONE REDUCTASES CODEXIS, INC. (US) 2010-07-29 — — US disclosed
US-20100190218-A1 ENONE REDUCTASES CODEXIS, INC. (US) 2010-07-29 — — US disclosed
US-20100190218-A1 ENONE REDUCTASES CODEXIS, INC. (US) 2010-07-29 — — US disclosed
WO-2010075574-A2 ENONE REDUCTASES CODEXIS, INC. (US) 2010-07-01 — — WO disclosed
WO-2010075574-A2 ENONE REDUCTASES CODEXIS, INC. (US) 2010-07-01 — — WO disclosed
US-4521344-A Cyano-dicarboxylate MONSANTO COMPANY (US) 1985-06-04 — — US disclosed
US-4514340-A Cyano-polycarboxylates MONSANTO COMPANY (US) 1985-04-30 — — US disclosed
US-4442298-A Chemical synthesis of ethylene/maleic anhydride dimer with phenylethyl end group MONSANTO COMPANY (US) 1984-04-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180312815-A1 ENONE REDUCTASES ENO1, DCXR, RRM2B SMN1; SMN2 2030/4885L3MBTL1 2438/4885MMP8 3574/4885
US-10995321-B2 Enone reductases ENO1, DCXR, RRM2B SMN1; SMN2 2030/4885L3MBTL1 2438/4885MMP8 3574/4885
US-20200040311-A1 ENONE REDUCTASES ENO1, DCXR, RRM2B SMN1; SMN2 2030/4885L3MBTL1 2438/4885MMP8 3574/4885
US-12371674-B2 Enone reductases ENO1, DCXR, RRM2B SMN1; SMN2 2030/4885L3MBTL1 2438/4885MMP8 3574/4885
US-20260043010-A1 ENONE REDUCTASES DCXR, ENY2, UPF1 SMN1; SMN2 1911/4885L3MBTL1 1368/4885MMP8 1360/4885
US-20100292292-A1 Treatment of Neurodegenerative Diseases Using Indatraline Analogs HTT, SNCA, PARK7 SMN1; SMN2 58/4885L3MBTL1 668/4885MMP8 4369/4885
US-20210324344-A1 ENONE REDUCTASES ENO1, DCXR, RRM2B SMN1; SMN2 2030/4885L3MBTL1 2438/4885MMP8 3574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.